Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001048 · ClinicalTrials.gov registry record · Phase 2
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
A Phase 2 study of HIV Infections and Leukoencephalopathy, Progressive Multifocal, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 9
- Study locations
NCT00001048: Completed Phase 2 study of HIV Infections and Leukoencephalopathy, Progressive Multifocal, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001048 is a Phase 2 study of HIV Infections and Leukoencephalopathy, Progressive Multifocal that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 90 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001048, a Phase 2 study of HIV Infections and Leukoencephalopathy, Progressive Multifocal, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 9
- Study locations
Study Summary
To compare the safety and efficacy of antiretroviral therapy (zidovudine plus either didanosine or dideoxycytidine) versus antiretroviral therapy plus intravenous cytarabine (Ara-C) versus antiretroviral therapy plus intrathecal Ara-C in the maintenance or improvement of neurological function over 6 months in HIV-infected individuals who have developed progressive multifocal leukoencephalopathy (PML). To compare the effect of these three treatment regimens on Karnofsky score and MRI studies. The effectiveness of Ara-C in the treatment of PML, caused by a human DNA papovavirus (designated JC virus) infection, has not been determined, although the most encouraging results have occurred with intrathecal administration of the drug.
Conditions Studied
Interventions
- DRUG Cytarabine
- DRUG Zidovudine
- DRUG Filgrastim
- DRUG Didanosine
- DRUG Zalcitabine
Study Locations (9)
Colorado
- University of Colorado Hospital CRS - Aurora
Florida
- Univ. of Miami AIDS CRS - Miami
Illinois
- Northwestern University CRS - Chicago
Maryland
- Johns Hopkins Adult AIDS CRS - Baltimore
Massachusetts
- Massachusetts General Hospital ACTG CRS - Boston
Missouri
- Washington U CRS - St Louis
New York
- Univ. of Rochester ACTG CRS - Rochester
North Carolina
- Unc Aids Crs - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Est. Completion | 1997-04 |
| Phase | Phase 2 |
What the finished NCT00001048 record still lists
NCT00001048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Cytarabine is the first listed.
NCT00001048 lists 9 locations in 9 states (Colorado, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT00001048 about?
NCT00001048 is a clinical study titled "Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients". To compare the safety and efficacy of antiretroviral therapy (zidovudine plus either didanosine or dideoxycytidine) versus antiretroviral therapy plus intravenous cytarabine (Ara-C) versus antiretroviral therapy plus intrathecal Ara-C in the maintenance or improvement of neurological function over 6...
What is the current status of trial NCT00001048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. Estimated completion is 1997-04.
What conditions does trial NCT00001048 study?
This clinical trial studies the following conditions: HIV Infections, Leukoencephalopathy, Progressive Multifocal.
What interventions are being tested in trial NCT00001048?
The interventions under investigation include: Cytarabine (DRUG), Zidovudine (DRUG), Filgrastim (DRUG), Didanosine (DRUG), Zalcitabine (DRUG).
Who is sponsoring clinical trial NCT00001048?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001048 being conducted?
This trial has 9 study locations across Colorado, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001048's enrollment target sits among peer trials
90 287th of 542 higher than 251 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery